EWM
VRNA

Endurance Wealth Management’s Verona Pharma VRNA Stock Holding History

Endurance Wealth Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,000
Closed -$20K – 663
2022
Q3 		$20K Hold
2,000
– – ﹤0.01% 407
2022
Q2 		$8K Hold
2,000
– – ﹤0.01% 507
2022
Q1 		$10K Hold
2,000
– – ﹤0.01% 516
2021
Q4 		$13K Buy
+2,000
New +$10.2K ﹤0.01% 483
2021
Q3 		– Sell
-2,000
Closed -$12K – 651
2021
Q2 		$12K Hold
2,000
– – ﹤0.01% 508
2021
Q1 		$17K Buy
+2,000
New +$16.6K ﹤0.01% 475

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Endurance Wealth Management's VRNA Position: Q4 2022 in Review

Endurance Wealth Management sold out of Verona Pharma (VRNA) in Q4 2022, closing a stake of 2,000 shares — an estimated $20K sold.

Endurance Wealth Management first reported a position in VRNA in Q1 2021 and held it in 6 quarters. The position peaked at $20K in Q3 2022. 89 funds tracked by Wall St. Rank hold VRNA as of Q4 2022.

  • Endurance Wealth Management reported no remaining Verona Pharma position as of Q4 2022 after selling out during the quarter.
  • Endurance Wealth Management sold 2,000 Verona Pharma shares in Q4 2022, an estimated $20K.
  • Endurance Wealth Management first reported a position in Verona Pharma in Q1 2021 and held it in 6 quarters.
  • Endurance Wealth Management's Verona Pharma position peaked at $20K in Q3 2022.
  • 89 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2022.

Based on Endurance Wealth Management's 13F filing for Q4 2022, filed 1 Feb 2023.